BIOGEN INC. Loss Contingency, Damages Sought, Value
BIOGEN INC. (BIIB) reported Loss Contingency, Damages Sought, Value of $200.00 million for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-06.
Discontinued › Notes › Commitment and Contingencies › Loss Contingency
us-gaap:LossContingencyDamagesSoughtValue · last filed 2023-02-15
- BIOGEN INC. loss contingency, damages sought, value for the quarter ending 2011-09-30 was $0.00.
- BIOGEN INC. loss contingency, damages sought, value for the quarter ending 2011-06-30 was $125.00M.
- BIOGEN INC. loss contingency, damages sought, value for fiscal 2019 was $200.00M.
| Period end | Loss Contingency, Damages Sought, Value 2 month | Loss Contingency, Damages Sought, Value 3 month | Loss Contingency, Damages Sought, Value 6 month | Loss Contingency, Damages Sought, Value 9 month | Loss Contingency, Damages Sought, Value 12 month |
|---|---|---|---|---|---|
| 2019-12-31 | $200.00M 10-K · filed 2023-02-15 | $200.00M 10-K · filed 2020-02-06 | |||
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-25 | $125.00M derived: sum of 2 quarters · filed 2012-10-25 | $125.00M 10-Q · filed 2012-10-25 | ||
| 2011-06-30 | $125.00M 10-Q · filed 2012-05-01 | $125.00M 10-Q · filed 2012-07-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |